$567 Million is the total value of TCG Crossover Management, LLC's 21 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 71.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ISEE | Buy | IVERIC BIO INC | $110,071,336 | +58.2% | 5,141,118 | +32.6% | 19.43% | -6.9% |
| MDGL | Buy | MADRIGAL PHARMACEUTICALS INC | $83,607,674 | +4187.6% | 288,054 | +860.2% | 14.76% | +2422.4% |
| COGT | Buy | COGENT BIOSCIENCES INC | $41,974,846 | -19.2% | 3,631,042 | +4.3% | 7.41% | -52.4% |
| GERN | Buy | GERON CORP | $36,752,717 | +29.6% | 15,187,073 | +25.3% | 6.49% | -23.7% |
| AVTE | Buy | AEROVATE THERAPEUTICS INC | $31,681,328 | +99.1% | 1,081,274 | +12.7% | 5.59% | +17.2% |
| New | VENTYX BIOSCIENCES, INC | $25,813,304 | – | 787,231 | +100.0% | 4.56% | – | |
| KALV | New | KALVISTA PHARMACEUTICALS, INC | $22,953,546 | – | 3,395,495 | +100.0% | 4.05% | – |
| VECT | New | VECTIVBIO HOLDING AG | $20,218,045 | – | 2,333,300 | +100.0% | 3.57% | – |
| KURA | Buy | KURA ONCOLOGY INC | $17,667,397 | -4.1% | 1,423,642 | +5.6% | 3.12% | -43.6% |
| IMVT | New | IMMUNOVANT, INC | $15,173,641 | – | 854,853 | +100.0% | 2.68% | – |
| Buy | TYRA BIOSCIENCES INC | $15,117,183 | +81.8% | 1,989,103 | +110.3% | 2.67% | +7.0% | |
| CABA | New | CABALETTA BIO, INC | $4,502,854 | – | 486,795 | +100.0% | 0.80% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COGENT BIOSCIENCES INC | 8 | Q3 2023 | 15.6% |
| AEROVATE THERAPEUTICS INC | 8 | Q3 2023 | 6.5% |
| TYRA BIOSCIENCES INC | 8 | Q3 2023 | 6.2% |
| ENTRADA THERAPEUTICS INC | 8 | Q3 2023 | 5.3% |
| MERUS N.V. | 8 | Q3 2023 | 3.4% |
| IVERIC BIO INC | 7 | Q2 2023 | 24.4% |
| Geron Corporation | 7 | Q3 2023 | 12.4% |
| ACLARIS THERAPEUTICS INC | 7 | Q2 2023 | 7.9% |
| KURA ONCOLOGY INC | 7 | Q3 2023 | 9.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q2 2023 | 7.6% |
View TCG Crossover Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Silence Therapeutics plc | August 19, 2022 | 6,314,625 | 5.9% |
| CymaBay Therapeutics, Inc. | November 29, 2021 | 5,905,400 | 7.0% |
| Cogent Biosciences, Inc. | November 17, 2021 | 2,716,042 | 6.8% |
| Tyra Biosciences, Inc. | September 29, 2021 | 937,500 | 2.2% |
| Viridian Therapeutics, Inc.\DE | September 29, 2021 | 1,314,000 | 8.2% |
View TCG Crossover Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| SC 13G | 2022-08-19 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-18 |
View TCG Crossover Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.